Capricor Therapeutics (CAPR) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 41.3% versus a gain of 8.0%. Over five years, CAPR leads with a +104.5% price change compared with -34.4% for OVID. Capricor Therapeutics is the larger company by market cap ($466.3 million vs $460.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | OVID |
|---|---|---|
| Share price | $8.02 | $2.36 |
| Market cap | $466.27M | $460.90M |
| 1-day change | -0.99% | 0.00% |
| YTD return | -71.93% | +44.79% |
| 1-year return | +8.00% | +41.32% |
| 5-year return | +104.55% | -34.44% |
| EPS (TTM) | $-2.45 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $3.11 |
| 52-week low | $2.96 | $1.18 |
| Distance from 52-week high | -80.13% | -23.99% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +236.66% | +155.08% |
| Average volume | 6.85M | 1.58M |
| Shares outstanding | 58.14M | 195.30M |
| Employees | 231 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed CAPR by 33.3 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
CAPR vs OVID FAQ
Which is bigger, Capricor Therapeutics or Ovid Therapeutics?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $466.27M compared with $460.90M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, CAPR or OVID?
OVID returned +41.32% over the past 12 months, compared with +8.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.